EGFR and lung carcinoma: The combination of EAI045 with cetuximab, an antibody that blocks EGFR dimerization, renders the kinase sensitive to EAI045 and was effective in a mice model of lung cancer driven by EGFR(L858R/T790M)- and EGFR(L858R/T790M/C797S) mutations [34].